Two Sigma Advisers
CRDL

Two Sigma Advisers’s Cardiol Therapeutics CRDL Stock Holding History

Two Sigma Advisers’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,100
Closed -$18.2K – 503
2025
Q4 		$18.2K Sell
19,100
-13,508
-41% -$14.1K ﹤0.01% 2316
2025
Q3 		$34.9K Buy
+32,608
New +$39.6K ﹤0.01% 2280
2024
Q2 		– Sell
-16,500
Closed -$29.9K – 2484
2024
Q1 		$29.9K Sell
16,500
-400
-2% -$539 ﹤0.01% 2377
2023
Q4 		$14.3K Hold
16,900
– – ﹤0.01% 2457
2023
Q3 		$15.1K Hold
16,900
– – ﹤0.01% 2334
2023
Q2 		$15K Sell
16,900
-5,500
-25% -$3.63K ﹤0.01% 2335
2023
Q1 		$10.9K Sell
22,400
-13,500
-38% -$7.99K ﹤0.01% 2540
2022
Q4 		$18.3K Hold
35,900
– – ﹤0.01% 2433
2022
Q3 		$37K Sell
35,900
-26,600
-43% -$32.4K ﹤0.01% 2394
2022
Q2 		$83K Sell
62,500
-36,800
-37% -$52.4K ﹤0.01% 2412
2022
Q1 		$152K Sell
99,300
-24,300
-20% -$40.1K ﹤0.01% 2431
2021
Q4 		$229K Buy
123,600
+92,500
+297% +$255K ﹤0.01% 2238
2021
Q3 		$129K Buy
+31,100
New +$113K ﹤0.01% 2303

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers's CRDL Position: Q1 2026 in Review

Two Sigma Advisers sold out of Cardiol Therapeutics (CRDL) in Q1 2026, closing a stake of 19,100 shares — an estimated $18.2K sold.

Two Sigma Advisers first reported a position in CRDL in Q3 2021 and held it in 13 quarters. The position peaked at $229K in Q4 2021. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Two Sigma Advisers reported no remaining Cardiol Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 19,100 Cardiol Therapeutics shares in Q1 2026, an estimated $18.2K.
  • Two Sigma Advisers first reported a position in Cardiol Therapeutics in Q3 2021 and held it in 13 quarters.
  • Two Sigma Advisers's Cardiol Therapeutics position peaked at $229K in Q4 2021.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.